| MeSH term | MeSH ID | Detail |
|---|---|---|
| Vestibulocochlear Nerve Diseases | D000160 | 1 associated lipids |
| Acromegaly | D000172 | 6 associated lipids |
| Actinobacillus Infections | D000189 | 4 associated lipids |
| Actinomycosis | D000196 | 2 associated lipids |
| Addison Disease | D000224 | 3 associated lipids |
| Adenocarcinoma | D000230 | 166 associated lipids |
| Adrenal Hyperplasia, Congenital | D000312 | 2 associated lipids |
| Albuminuria | D000419 | 18 associated lipids |
| Alzheimer Disease | D000544 | 76 associated lipids |
| Angina, Unstable | D000789 | 14 associated lipids |
7-octadecynoic acid
7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
Cross Reference
There are no associated biomedical information in the current reference collection.
Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.
Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.
Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
All references with 7-octadecynoic acid
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Saika M et al. | 17beta-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-alpha. | 2001 | Endocrinology | pmid:11356664 |
| Mackie PS et al. | Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line. | 2001 | Br. J. Cancer | pmid:11286476 |
| Hofbauer LC et al. | Osteoprotegerin, RANK, and RANK ligand: the good, the bad, and the ugly in rheumatoid arthritis. | 2001 | J. Rheumatol. | pmid:11327234 |
| Hofbauer LC and Heufelder AE | The role of osteoprotegerin and receptor activator of nuclear factor kappaB ligand in the pathogenesis and treatment of rheumatoid arthritis. | 2001 | Arthritis Rheum. | pmid:11229454 |
| Leach RJ et al. | The genetics of Paget's disease of the bone. | 2001 | J. Clin. Endocrinol. Metab. | pmid:11231972 |
| Luger NM et al. | Osteoprotegerin diminishes advanced bone cancer pain. | 2001 | Cancer Res. | pmid:11358823 |
| Kikuchi T et al. | Gene expression of osteoclast differentiation factor is induced by lipopolysaccharide in mouse osteoblasts via Toll-like receptors. | 2001 | J. Immunol. | pmid:11207318 |
| O'Brien EA et al. | Osteoprotegerin is produced when prostaglandin synthesis is inhibited causing osteoclasts to detach from the surface of mouse parietal bone and attach to the endocranial membrane. | 2001 | Bone | pmid:11182380 |
| Zhang YH et al. | Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. | 2001 | J. Biol. Chem. | pmid:11032840 |
| Goltzman D | Osteolysis and cancer. | 2001 | J. Clin. Invest. | pmid:11375409 |
| Zhang J et al. | Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. | 2001 | J. Clin. Invest. | pmid:11375413 |
| Kostenuik PJ and Shalhoub V | Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. | 2001 | Curr. Pharm. Des. | pmid:11375772 |
| Thirunavukkarasu K et al. | Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-beta (TGF-beta). Mapping of the OPG promoter region that mediates TGF-beta effects. | 2001 | J. Biol. Chem. | pmid:11451955 |
| Yun TJ et al. | Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function. | 2001 | J. Immunol. | pmid:11160187 |
| Lories RJ and Luyten FP | Osteoprotegerin and osteoprotegerin-ligand balance: a new paradigm in bone metabolism providing new therapeutic targets. | 2001 | Clin. Rheumatol. | pmid:11254237 |
| Wan M et al. | Transcriptional mechanisms of bone morphogenetic protein-induced osteoprotegrin gene expression. | 2001 | J. Biol. Chem. | pmid:11139569 |
| Browner WS et al. | Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. | 2001 | J. Clin. Endocrinol. Metab. | pmid:11158021 |
| Hofbauer LC and Heufelder AE | [Osteoprotegerin ligand and osteoprotegerin: new concepts of the pathogenesis and therapy of metabolic bone diseases]. | 2001 | Dtsch. Med. Wochenschr. | pmid:11233883 |
| Bolon B et al. | Adenoviral delivery of osteoprotegerin ameliorates bone resorption in a mouse ovariectomy model of osteoporosis. | 2001 | Mol. Ther. | pmid:11237676 |
| Sasaki N et al. | Glucocorticoid decreases circulating osteoprotegerin (OPG): possible mechanism for glucocorticoid induced osteoporosis. | 2001 | Nephrol. Dial. Transplant. | pmid:11239019 |
| Takeuchi T et al. | Adrenergic stimulation of osteoclastogenesis mediated by expression of osteoclast differentiation factor in MC3T3-E1 osteoblast-like cells. | 2001 | Biochem. Pharmacol. | pmid:11239501 |
| Mori K et al. | Cross-talk between RANKL and FRP-1/CD98 Systems: RANKL-mediated osteoclastogenesis is suppressed by an inhibitory anti-CD98 heavy chain mAb and CD98-mediated osteoclastogenesis is suppressed by osteoclastogenesis inhibitory factor. | 2001 | Cell. Immunol. | pmid:11243701 |
| Hofbauer LC et al. | Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. | 2001 | Biochem. Biophys. Res. Commun. | pmid:11162519 |
| Brändström H et al. | Regulation of osteoprotegerin secretion from primary cultures of human bone marrow stromal cells. | 2001 | Biochem. Biophys. Res. Commun. | pmid:11162596 |
| Wuyts W et al. | Evaluation of the role of RANK and OPG genes in Paget's disease of bone. | 2001 | Bone | pmid:11165949 |
| Michigami T et al. | Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. | 2001 | Cancer Res. | pmid:11245477 |
| Wada N et al. | Periodontal ligament cells secrete the factor that inhibits osteoclastic differentiation and function: the factor is osteoprotegerin/osteoclastogenesis inhibitory factor. | 2001 | J. Periodont. Res. | pmid:11246705 |
| Jung K et al. | Osteoprotegerin in serum as a novel marker of bone metastatic spread in prostate cancer. | 2001 | Clin. Chem. | pmid:11673385 |
| Lean JM et al. | FLT3 ligand can substitute for macrophage colony-stimulating factor in support of osteoclast differentiation and function. | 2001 | Blood | pmid:11675341 |
| Fiumara P et al. | Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines. | 2001 | Blood | pmid:11675352 |
| Satoh K et al. | Tumor necrosis factor-related apoptosis-inducing ligand and its receptor expression and the pathway of apoptosis in human pancreatic cancer. | 2001 | Pancreas | pmid:11590320 |
| Yano K et al. | Immunological study on circulating murine osteoprotegerin/osteoclastogenesis inhibitory factor (OPG/OCIF): possible role of OPG/OCIF in the prevention of osteoporosis in pregnancy. | 2001 | Biochem. Biophys. Res. Commun. | pmid:11594776 |
| Brown JM et al. | Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. | 2001 | Clin. Cancer Res. | pmid:11595685 |
| Feuerherm AJ et al. | Elevated levels of osteoprotegerin (OPG) and hepatocyte growth factor (HGF) in rheumatoid arthritis. | 2001 | Scand. J. Rheumatol. | pmid:11578019 |
| Sakai E et al. | Characterization of phagosomal subpopulations along endocytic routes in osteoclasts and macrophages. | 2001 | J. Biochem. | pmid:11726283 |
| Quinn JM et al. | Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions. | 2001 | J. Bone Miner. Res. | pmid:11585342 |
| Choi SJ et al. | Osteoclast inhibitory peptide 2 inhibits osteoclast formation via its C-terminal fragment. | 2001 | J. Bone Miner. Res. | pmid:11585344 |
| Miyamoto T et al. | Bifurcation of osteoclasts and dendritic cells from common progenitors. | 2001 | Blood | pmid:11588053 |
| Pearse RN et al. | Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. | 2001 | Proc. Natl. Acad. Sci. U.S.A. | pmid:11562486 |
| Kostenuik PJ et al. | OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats. | 2001 | Endocrinology | pmid:11564687 |
| Marco-Mingot M et al. | Lack of mutations in the RANK gene in Spanish patients with Paget disease of bone. | 2001 | Clin. Genet. | pmid:11531977 |
| Raffai RL et al. | Introduction of human apolipoprotein E4 "domain interaction" into mouse apolipoprotein E. | 2001 | Proc. Natl. Acad. Sci. U.S.A. | pmid:11553788 |
| Hocking LJ et al. | Genomewide search in familial Paget disease of bone shows evidence of genetic heterogeneity with candidate loci on chromosomes 2q36, 10p13, and 5q35. | 2001 | Am. J. Hum. Genet. | pmid:11555792 |
| Hofbauer LC et al. | Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. | 2001 | Cancer | pmid:11505389 |
| Hofbauer LC and Heufelder AE | Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. | 2001 | J. Mol. Med. | pmid:11485016 |
| Furuya D et al. | Immuno-PCR assay for homodimeric osteoprotegerin. | 2001 | Clin. Chem. | pmid:11468243 |
| Seck T et al. | Serum parathyroid hormone, but not menopausal status, is associated with the expression of osteoprotegerin and RANKL mRNA in human bone samples. | 2001 | Eur. J. Endocrinol. | pmid:11454517 |
| Burguera B et al. | Leptin reduces ovariectomy-induced bone loss in rats. | 2001 | Endocrinology | pmid:11459801 |
| Yamagishi T et al. | Reciprocal control of expression of mRNAs for osteoclast differentiation factor and OPG in osteogenic stromal cells by genistein: evidence for the involvement of topoisomerase II in osteoclastogenesis. | 2001 | Endocrinology | pmid:11459812 |
| Ma YL et al. | Catabolic effects of continuous human PTH (1--38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. | 2001 | Endocrinology | pmid:11517184 |
| Bateman TA et al. | Osteoprotegerin ameliorates sciatic nerve crush induced bone loss. | 2001 | J. Orthop. Res. | pmid:11518255 |
| Myoung H et al. | Effects of a bisphosphonate on the expression of bone specific genes after autogenous free bone grafting in rats. | 2001 | J. Periodont. Res. | pmid:11519698 |
| Halladay DL et al. | Identification of signal transduction pathways and promoter sequences that mediate parathyroid hormone 1-38 inhibition of osteoprotegerin gene expression. | 2001 | J. Cell. Biochem. | pmid:11746511 |
| Cao Y et al. | IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. | 2001 | Cell | pmid:11747812 |
| Chung H et al. | Deflazacort increases osteoclast formation in mouse bone marrow culture and the ratio of RANKL/OPG mRNA expression in marrow stromal cells. | 2001 | J. Korean Med. Sci. | pmid:11748360 |
| Komuro H et al. | The osteoprotegerin/receptor activator of nuclear factor kappaB/receptor activator of nuclear factor kappaB ligand system in cartilage. | 2001 | Arthritis Rheum. | pmid:11762937 |
| Lindberg MK et al. | Estrogen receptor alpha, but not estrogen receptor beta, is involved in the regulation of the OPG/RANKL (osteoprotegerin/receptor activator of NF-kappa B ligand) ratio and serum interleukin-6 in male mice. | 2001 | J. Endocrinol. | pmid:11739008 |
| Wise GE et al. | Effects of dexamethasone on tooth eruption in rats: differences in incisor and molar eruption. | 2001 | Clin Anat | pmid:11301468 |
| Atkins GJ et al. | Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone. | 2001 | Bone | pmid:11336917 |
| Komine M et al. | Tumor necrosis factor-alpha cooperates with receptor activator of nuclear factor kappaB ligand in generation of osteoclasts in stromal cell-depleted rat bone marrow cell culture. | 2001 | Bone | pmid:11344046 |
| Chen D et al. | ELISA methodology for detection of modified osteoprotegerin in clinical studies. | 2001 | Clin. Chem. | pmid:11274028 |
| Collin-Osdoby P et al. | Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. | 2001 | J. Biol. Chem. | pmid:11274143 |
| Brown JM et al. | Osteoprotegerin and rank ligand expression in prostate cancer. | 2001 | Urology | pmid:11306358 |
| Fukagawa M et al. | [PTH and bone metabolism in chronic dialysis patients]. | 2001 | Rinsho Byori | pmid:11307321 |
| Horowitz MC et al. | Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands. | 2001 | Cytokine Growth Factor Rev. | pmid:11312114 |
| Lin DL et al. | Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. | 2001 | Prostate | pmid:11351351 |
| Sparks AB et al. | Mutation screening of the TNFRSF11A gene encoding receptor activator of NF kappa B (RANK) in familial and sporadic Paget's disease of bone and osteosarcoma. | 2001 | Calcif. Tissue Int. | pmid:11351498 |
| Disthabanchong S and González EA | Regulation of bone cell development and function: implication for renal osteodystrophy. | 2001 | J. Investig. Med. | pmid:11352181 |
| Kotake S et al. | Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. | 2001 | Arthritis Rheum. | pmid:11352231 |
| Yan T et al. | Regulation of osteoclastogenesis and RANK expression by TGF-beta1. | 2001 Aug 1-9 | J. Cell. Biochem. | pmid:11573248 |
| Rosa-Rañal M et al. | [New paradigms in the regulation of bone metabolism]. | 2001 Jul-Aug | Rev. Invest. Clin. | pmid:11599485 |
| Juji T et al. | A novel therapeutic vaccine approach, targeting RANKL, prevents bone destruction in bone-related disorders. | 2002 | J. Bone Miner. Metab. | pmid:12203031 |
| Grisar J et al. | Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formation. | 2002 | J. Rheumatol. | pmid:12136902 |
| Hofbauer LC et al. | Regulation of osteoprotegerin production by androgens and anti-androgens in human osteoblastic lineage cells. | 2002 | Eur. J. Endocrinol. | pmid:12153751 |
| Mundy GR | Metastasis to bone: causes, consequences and therapeutic opportunities. | 2002 | Nat. Rev. Cancer | pmid:12154351 |
| Lorget F et al. | Lactoferrin reduces in vitro osteoclast differentiation and resorbing activity. | 2002 | Biochem. Biophys. Res. Commun. | pmid:12163011 |
| Ulrich-Vinther M et al. | Recombinant adeno-associated virus-mediated osteoprotegerin gene therapy inhibits wear debris-induced osteolysis. | 2002 | J Bone Joint Surg Am | pmid:12177271 |
| Ohmori H et al. | Linkage and association analyses of the osteoprotegerin gene locus with human osteoporosis. | 2002 | J. Hum. Genet. | pmid:12181640 |
| Price PA et al. | Bone origin of the serum complex of calcium, phosphate, fetuin, and matrix Gla protein: biochemical evidence for the cancellous bone-remodeling compartment. | 2002 | J. Bone Miner. Res. | pmid:12096831 |
| Xing L et al. | NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis. | 2002 | J. Bone Miner. Res. | pmid:12096833 |
| Zou W and Bar-Shavit Z | Dual modulation of osteoclast differentiation by lipopolysaccharide. | 2002 | J. Bone Miner. Res. | pmid:12096834 |
| Koyama H et al. | Melatonin at pharmacologic doses increases bone mass by suppressing resorption through down-regulation of the RANKL-mediated osteoclast formation and activation. | 2002 | J. Bone Miner. Res. | pmid:12096835 |
| Langdahl BL et al. | Polymorphisms in the osteoprotegerin gene are associated with osteoporotic fractures. | 2002 | J. Bone Miner. Res. | pmid:12096838 |
| Zhang J et al. | Osteoprotegerin abrogates chronic alcohol ingestion-induced bone loss in mice. | 2002 | J. Bone Miner. Res. | pmid:12096839 |
| Biskobing DM et al. | Novel therapeutic options for osteoporosis. | 2002 | Curr Opin Rheumatol | pmid:12118183 |
| Mizukami J et al. | Receptor activator of NF-kappaB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6. | 2002 | Mol. Cell. Biol. | pmid:11809792 |
| Wynne F et al. | Investigation of the genetic influence of the OPG, VDR (Fok1), and COLIA1 Sp1 polymorphisms on BMD in the Irish population. | 2002 | Calcif. Tissue Int. | pmid:12073153 |
| Lubberts E et al. | Increase in expression of receptor activator of nuclear factor kappaB at sites of bone erosion correlates with progression of inflammation in evolving collagen-induced arthritis. | 2002 | Arthritis Rheum. | pmid:12428250 |
| Crotti TN et al. | Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. | 2002 | Ann. Rheum. Dis. | pmid:12429533 |
| Hofbauer LC and Schoppet M | Osteoprotegerin deficiency and juvenile Paget's disease. | 2002 | N. Engl. J. Med. | pmid:12432053 |
| Jono S et al. | Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. | 2002 | Circulation | pmid:12208791 |
| Stajszczyk M | [Role of receptor activator of nuclear factor kappa B (RANK), its ligand (RANK-L) and osteoprotegerin (OPG) in bone metabolism]. | 2002 | Pol. Arch. Med. Wewn. | pmid:12600190 |
| Fahrleitner A et al. | Serum osteoprotegerin levels in patients after liver transplantation and correlation to bone turnover, bone mineral density and fracture status. | 2002 | Wien. Klin. Wochenschr. | pmid:12602117 |
| Theill LE et al. | RANK-L and RANK: T cells, bone loss, and mammalian evolution. | 2002 | Annu. Rev. Immunol. | pmid:11861618 |
| Yamashita T et al. | Double mutations in klotho and osteoprotegerin gene loci rescued osteopetrotic phenotype. | 2002 | Endocrinology | pmid:12446599 |
| Takayanagi H | [Cross-talk between immune and skeletal systems]. | 2002 | Nippon Rinsho | pmid:12510352 |
| Mochizuki S et al. | Osteoclastogenesis inhibitory factor/osteoprotegerin ameliorates the decrease in both bone mineral density and bone strength in immobilized rats. | 2002 | J. Bone Miner. Metab. | pmid:11810411 |
| Childs LM et al. | In vivo RANK signaling blockade using the receptor activator of NF-kappaB:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis. | 2002 | J. Bone Miner. Res. | pmid:11811549 |
| Holloway WR et al. | Leptin inhibits osteoclast generation. | 2002 | J. Bone Miner. Res. | pmid:11811550 |
| Coen G et al. | Serum osteoprotegerin and renal osteodystrophy. | 2002 | Nephrol. Dial. Transplant. | pmid:11812872 |